Tiziana Life SciencesTLSA
About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Employees: 9
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
98% more capital invested
Capital invested by funds: $431K [Q1] → $854K (+$423K) [Q2]
35% more funds holding
Funds holding: 20 [Q1] → 27 (+7) [Q2]
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.02% less ownership
Funds ownership: 0.92% [Q1] → 0.91% (-0.02%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TLSA.